TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06563258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex Balance Training
Description: Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vibration device
Description: WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercises
Description: 1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercises
Description: 1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)
Study: NCT06242145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT06561451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracytoplasmic sperm injection and artificial oocyte activation
Description: A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracytoplasmic sperm injection
Description: A single sperm will be injected within 4 hours after the follicular aspiration.
Study: NCT05832658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With EMG-Biofeedback
Description: Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Without EMG-Biofeedback
Description: Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
Study: NCT03734484

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InSight
Description: The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
Study: NCT04672681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play-based physical activity intervention
Description: The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
Study: NCT05916287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and urine samples
Description: Blood and urine samples

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxneuvance
Description: The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study: NCT05916287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular assessment
Description: Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intake
Description: Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthropometric parameters
Description: Measurement of height, weight, abdominal circumference, hip circumference, arm circumference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic parameters
Description: Systolic pressure index measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic parameters
Description: Heart rate measurements, blood pressure measurements, orthostatic BP measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic parameters
Description: Blood pressure measurements by unattended BP monitor over 5 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic parameters
Description: Electrocardiogram
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxneuvance
Description: The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study: NCT05916287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of compliance with antihypertensive treatments for treated participants
Description: EVALOBS scale and compliance questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory 24 hours measurment of blood pressure
Description: For the first 100 patients willing to participate
Study: NCT05491187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine heavy
Description: Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine heavy with fentanyl
Description: Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
Study: NCT06352138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.
Description: comparison vs the reference product to demonstrate biological similarity

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: European Union licenced epoetin alfa
Description: comparison vs. the test product to demonstrate biological similarity
Study: NCT06555458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient group to be given dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patient group to be given salin
Study: NCT05916287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24 hours urinary collection
Description: For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General questionnaires
Description: Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Women specific questionnaire
Description: Women specific questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women specific questionnaire
Description: Women specific questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NYHA dyspnea questionnaire
Description: Determination of NYHA class.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety questionnaire
Description: Assessment of anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale
Description: sleep quality assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A questionnaire on the perception of the management of cardiovascular risk factors
Description: Patient's evaluation of cardiovascular risk factors by the health system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A questionnaire on eating behaviors
Description: Assessment of eating behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A questionnaire on eating habits to determine consumer profiles
Description: Assessement of eating habit to create a consumer profile

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A questionnaire on food supplements use
Description: Evaluation od food supplements intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Infection Questionnaire
Description: SARS-CoV-2 Infection Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instantaneous expired air analysis
Description: Carbon monoxyde analysis in expired air

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capillary sampling
Description: Capillary sampling for pollutant analysis (Optional)
Study: NCT05391087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mean arterial pressure based management
Description: Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac index based management
Description: Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
Study: NCT04266938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rapid start of antiretrovirals
Description: Utilize health navigators to link patients with newly diagnosed HIV into care and treatment within 7 days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrospective analysis
Description: Review historical standard of care relative to time to start antiretrovirals and impact on retention in care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non- RAPID start
Description: Review of patients who failed to establish care and start ART within 7 days of HIV diagnosis and analyze impact on retention in care.
Study: NCT06567340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StratCare
Description: The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
Study: NCT04861038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aerSleep II
Description: Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
Study: NCT06370247

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K
Description: HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K will measure
Study: NCT04941911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Acetate
Description: Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% w/v
Study: NCT05852392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted PARENT Model
Description: PARENT is a team-based approach to care that utilizes a clinic-based community health worker as part of the WCC team to provide comprehensive and family-centered preventive care services.
Study: NCT06455137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulator
Description: Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
Study: NCT06562127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIN-Vets
Description: The TRAIN-Vets intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in monthly lifestyle coaching based at SFVAHCS focused on other risk factors and symptoms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education Control
Description: The Health Education Control (HEC) receives mailed educational materials about brain health and healthy lifestyles over 8 months, as well as regular contact with study staff.
Study: NCT05572398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAC-T
Description: Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
Study: NCT06095401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inelastic adjustable compression garment (INCOM)
Description: Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic compression garment (CONTROL)
Description: Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
Study: NCT04811235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infra-Red Spectroscopy (NIRS) Sensor
Description: The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
Study: NCT06274437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BND-35
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BND-35
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BND-35
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BND-35
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BND-35
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT05029362

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SmokefreeSGM
Description: Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
Study: NCT05514899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: THC capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: THC capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: oral solution
Study: NCT06377085

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for the AZA 10mg/m^2
Description: Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for the AZA 20mg/m^2
Description: Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for the AZA 35mg/m^2
Description: Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for the AZA 75mg/m^2
Description: Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine 10mg/m^2
Description: 5-Azacytidine 10mg/m\^2, one-time subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine 20mg/m^2
Description: 5-Azacytidine 20mg/m\^2, one-time subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine 35mg/m^2
Description: 5-Azacytidine 35mg/m\^2, one-time subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine 75mg/m^2
Description: 5-Azacytidine 75mg/m\^2, one-time subcutaneous injection